Match each clinical presentation of a patient requiring initiation of antihypertensive therapy to the single most appropriate pharmacological class based on compelling indications and secondary clinical benefits.
- A 42-year-old woman with severe, episodic digital pallor and cyanosis upon cold exposureDihydropyridine calcium channel blocker
- A 58-year-old man with a history of recurrent renal calcium oxalate stonesThiazide diuretic
- A 64-year-old man with stable exertional chest pressure relieved by restCardioselective beta-blocker
- A 35-year-old woman with type 1 diabetes mellitus and persistent microalbuminuriaAngiotensin-converting enzyme inhibitor
Cevap
The correct matches align each patient's secondary comorbidity with the mechanistic benefit of specific antihypertensive classes: the patient with Raynaud phenomenon matches with a dihydropyridine calcium channel blocker; the patient with recurrent calcium oxalate stones matches with a thiazide diuretic; the patient with stable angina matches with a cardioselective beta-blocker; and the patient with diabetic nephropathy matches with an angiotensin-converting enzyme inhibitor.
Each correct pairing utilizes the pharmacological mechanism of an antihypertensive class to treat both the high blood pressure and a specific underlying condition. Dihydropyridine calcium channel blockers vasodilate peripheral vessels (benefiting Raynaud phenomenon). Thiazide diuretics enhance distal tubule calcium reabsorption (preventing calcium stones). Beta-blockers slow heart rate and contractility (relieving angina). ACE inhibitors dilate the efferent arteriole (protecting the kidneys in diabetes).
Adım Adım Çözüm
Anahtar Kavram
Selection of antihypertensive therapy must be individualized based on compelling patient comorbidities and the secondary physiologic mechanisms of the medication.